News
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...
3h
Stocktwits on MSNSarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy — Retail Eyes ReboundSarepta Therapeutics shares surged 34% in after-hours trading on Wednesday after the company said it would slash 500 jobs, or ...
The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys.
CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...
Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...
The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...
Groundbreaking new research shows that it is possible to use gene therapy to restore hearing in both children and adults.
This is the first time such results have been achieved in both children and adult patients born with a specific type of ...
1d
News-Medical.Net on MSNNew cellular entry pathway improves gene therapy outcomesScientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer ...
In his first 100 days as commissioner of the Food and Drug Administration, Marty Makary has made a handful of splashy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results